0001214659-19-001445.txt : 20190222 0001214659-19-001445.hdr.sgml : 20190222 20190222190012 ACCESSION NUMBER: 0001214659-19-001445 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190220 FILED AS OF DATE: 20190222 DATE AS OF CHANGE: 20190222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CARTER BRUCE L A CENTRAL INDEX KEY: 0001225503 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 19627723 MAIL ADDRESS: STREET 1: C/O ZYMOGENETICS, INC. STREET 2: 1201 EASTLAKE AVENUE CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-44184.xml PRIMARY DOCUMENT X0306 4 2019-02-20 0001576263 Mirati Therapeutics, Inc. MRTX 0001225503 CARTER BRUCE L A C/O MIRATI THERAPEUTICS, INC 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 true false false false Common Stock 2019-02-20 4 M false 3000 6.78 A 3000 D Common Stock 2019-02-20 4 S false 900 72.5000 D 2100 D Common Stock 2019-02-20 4 S false 1000 73.7890 D 1100 D Common Stock 2019-02-20 4 S false 1100 74.4382 D 0 D Non-Qualified Stock Option (right to buy) 6.78 2019-02-20 4 M false 3000 0 D 2026-09-26 Common Stock 3000 22000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018. This transaction was executed in multiple trades at prices ranging from $71.82 to $72.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $73.13 to $74.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $74.17 to $74.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. /s/ Vickie Reed, Attorney-in-Fact 2019-02-22